Nymox Nears Completion Of New One Year U.S. Study Of Benign Prostatic Hyperplasia Drug

Nymox Pharmaceutical Corporation (NASDAQ: NYMX) announced today that the Company’s latest multi-center U.S. study of NX-1207, its investigational drug for the treatment of benign prostatic hyperplasia (BPH), is nearing completion. The Company anticipates the reporting of final results and statistical analysis for the study within the next 2-3 weeks. The new study concerns assessment of the one year efficacy effects of a single treatment of NX-1207.

More: continued here

Filed under: Prostate on October 27th, 2008